Cargando…

Plasma Metabolomic and Lipidomic Profiling of Metabolic Dysfunction-Associated Fatty Liver Disease in Humans Using an Untargeted Multiplatform Approach

Metabolic dysfunction-associated fatty liver disease (MAFLD) is a complex disorder that is implicated in dysregulations in multiple biological pathways, orchestrated by interactions between genetic predisposition, metabolic syndromes and environmental factors. The limited knowledge of its pathogenes...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Xiangping, Liu, Xinyu, Triba, Mohamed N., Bouchemal, Nadia, Liu, Zhicheng, Walker, Douglas I., Palama, Tony, Le Moyec, Laurence, Ziol, Marianne, Helmy, Nada, Vons, Corinne, Xu, Guowang, Prip-Buus, Carina, Savarin, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9693407/
https://www.ncbi.nlm.nih.gov/pubmed/36355164
http://dx.doi.org/10.3390/metabo12111081
_version_ 1784837533853548544
author Lin, Xiangping
Liu, Xinyu
Triba, Mohamed N.
Bouchemal, Nadia
Liu, Zhicheng
Walker, Douglas I.
Palama, Tony
Le Moyec, Laurence
Ziol, Marianne
Helmy, Nada
Vons, Corinne
Xu, Guowang
Prip-Buus, Carina
Savarin, Philippe
author_facet Lin, Xiangping
Liu, Xinyu
Triba, Mohamed N.
Bouchemal, Nadia
Liu, Zhicheng
Walker, Douglas I.
Palama, Tony
Le Moyec, Laurence
Ziol, Marianne
Helmy, Nada
Vons, Corinne
Xu, Guowang
Prip-Buus, Carina
Savarin, Philippe
author_sort Lin, Xiangping
collection PubMed
description Metabolic dysfunction-associated fatty liver disease (MAFLD) is a complex disorder that is implicated in dysregulations in multiple biological pathways, orchestrated by interactions between genetic predisposition, metabolic syndromes and environmental factors. The limited knowledge of its pathogenesis is one of the bottlenecks in the development of prognostic and therapeutic options for MAFLD. Moreover, the extent to which metabolic pathways are altered due to ongoing hepatic steatosis, inflammation and fibrosis and subsequent liver damage remains unclear. To uncover potential MAFLD pathogenesis in humans, we employed an untargeted nuclear magnetic resonance (NMR) spectroscopy- and high-resolution mass spectrometry (HRMS)-based multiplatform approach combined with a computational multiblock omics framework to characterize the plasma metabolomes and lipidomes of obese patients without (n = 19) or with liver biopsy confirmed MAFLD (n = 63). Metabolite features associated with MAFLD were identified using a metabolome-wide association study pipeline that tested for the relationships between feature responses and MAFLD. A metabolic pathway enrichment analysis revealed 16 pathways associated with MAFLD and highlighted pathway changes, including amino acid metabolism, bile acid metabolism, carnitine shuttle, fatty acid metabolism, glycerophospholipid metabolism, arachidonic acid metabolism and steroid metabolism. These results suggested that there were alterations in energy metabolism, specifically amino acid and lipid metabolism, and pointed to the pathways being implicated in alerted liver function, mitochondrial dysfunctions and immune system disorders, which have previously been linked to MAFLD in human and animal studies. Together, this study revealed specific metabolic alterations associated with MAFLD and supported the idea that MAFLD is fundamentally a metabolism-related disorder, thereby providing new perspectives for diagnostic and therapeutic strategies.
format Online
Article
Text
id pubmed-9693407
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96934072022-11-26 Plasma Metabolomic and Lipidomic Profiling of Metabolic Dysfunction-Associated Fatty Liver Disease in Humans Using an Untargeted Multiplatform Approach Lin, Xiangping Liu, Xinyu Triba, Mohamed N. Bouchemal, Nadia Liu, Zhicheng Walker, Douglas I. Palama, Tony Le Moyec, Laurence Ziol, Marianne Helmy, Nada Vons, Corinne Xu, Guowang Prip-Buus, Carina Savarin, Philippe Metabolites Article Metabolic dysfunction-associated fatty liver disease (MAFLD) is a complex disorder that is implicated in dysregulations in multiple biological pathways, orchestrated by interactions between genetic predisposition, metabolic syndromes and environmental factors. The limited knowledge of its pathogenesis is one of the bottlenecks in the development of prognostic and therapeutic options for MAFLD. Moreover, the extent to which metabolic pathways are altered due to ongoing hepatic steatosis, inflammation and fibrosis and subsequent liver damage remains unclear. To uncover potential MAFLD pathogenesis in humans, we employed an untargeted nuclear magnetic resonance (NMR) spectroscopy- and high-resolution mass spectrometry (HRMS)-based multiplatform approach combined with a computational multiblock omics framework to characterize the plasma metabolomes and lipidomes of obese patients without (n = 19) or with liver biopsy confirmed MAFLD (n = 63). Metabolite features associated with MAFLD were identified using a metabolome-wide association study pipeline that tested for the relationships between feature responses and MAFLD. A metabolic pathway enrichment analysis revealed 16 pathways associated with MAFLD and highlighted pathway changes, including amino acid metabolism, bile acid metabolism, carnitine shuttle, fatty acid metabolism, glycerophospholipid metabolism, arachidonic acid metabolism and steroid metabolism. These results suggested that there were alterations in energy metabolism, specifically amino acid and lipid metabolism, and pointed to the pathways being implicated in alerted liver function, mitochondrial dysfunctions and immune system disorders, which have previously been linked to MAFLD in human and animal studies. Together, this study revealed specific metabolic alterations associated with MAFLD and supported the idea that MAFLD is fundamentally a metabolism-related disorder, thereby providing new perspectives for diagnostic and therapeutic strategies. MDPI 2022-11-08 /pmc/articles/PMC9693407/ /pubmed/36355164 http://dx.doi.org/10.3390/metabo12111081 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lin, Xiangping
Liu, Xinyu
Triba, Mohamed N.
Bouchemal, Nadia
Liu, Zhicheng
Walker, Douglas I.
Palama, Tony
Le Moyec, Laurence
Ziol, Marianne
Helmy, Nada
Vons, Corinne
Xu, Guowang
Prip-Buus, Carina
Savarin, Philippe
Plasma Metabolomic and Lipidomic Profiling of Metabolic Dysfunction-Associated Fatty Liver Disease in Humans Using an Untargeted Multiplatform Approach
title Plasma Metabolomic and Lipidomic Profiling of Metabolic Dysfunction-Associated Fatty Liver Disease in Humans Using an Untargeted Multiplatform Approach
title_full Plasma Metabolomic and Lipidomic Profiling of Metabolic Dysfunction-Associated Fatty Liver Disease in Humans Using an Untargeted Multiplatform Approach
title_fullStr Plasma Metabolomic and Lipidomic Profiling of Metabolic Dysfunction-Associated Fatty Liver Disease in Humans Using an Untargeted Multiplatform Approach
title_full_unstemmed Plasma Metabolomic and Lipidomic Profiling of Metabolic Dysfunction-Associated Fatty Liver Disease in Humans Using an Untargeted Multiplatform Approach
title_short Plasma Metabolomic and Lipidomic Profiling of Metabolic Dysfunction-Associated Fatty Liver Disease in Humans Using an Untargeted Multiplatform Approach
title_sort plasma metabolomic and lipidomic profiling of metabolic dysfunction-associated fatty liver disease in humans using an untargeted multiplatform approach
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9693407/
https://www.ncbi.nlm.nih.gov/pubmed/36355164
http://dx.doi.org/10.3390/metabo12111081
work_keys_str_mv AT linxiangping plasmametabolomicandlipidomicprofilingofmetabolicdysfunctionassociatedfattyliverdiseaseinhumansusinganuntargetedmultiplatformapproach
AT liuxinyu plasmametabolomicandlipidomicprofilingofmetabolicdysfunctionassociatedfattyliverdiseaseinhumansusinganuntargetedmultiplatformapproach
AT tribamohamedn plasmametabolomicandlipidomicprofilingofmetabolicdysfunctionassociatedfattyliverdiseaseinhumansusinganuntargetedmultiplatformapproach
AT bouchemalnadia plasmametabolomicandlipidomicprofilingofmetabolicdysfunctionassociatedfattyliverdiseaseinhumansusinganuntargetedmultiplatformapproach
AT liuzhicheng plasmametabolomicandlipidomicprofilingofmetabolicdysfunctionassociatedfattyliverdiseaseinhumansusinganuntargetedmultiplatformapproach
AT walkerdouglasi plasmametabolomicandlipidomicprofilingofmetabolicdysfunctionassociatedfattyliverdiseaseinhumansusinganuntargetedmultiplatformapproach
AT palamatony plasmametabolomicandlipidomicprofilingofmetabolicdysfunctionassociatedfattyliverdiseaseinhumansusinganuntargetedmultiplatformapproach
AT lemoyeclaurence plasmametabolomicandlipidomicprofilingofmetabolicdysfunctionassociatedfattyliverdiseaseinhumansusinganuntargetedmultiplatformapproach
AT ziolmarianne plasmametabolomicandlipidomicprofilingofmetabolicdysfunctionassociatedfattyliverdiseaseinhumansusinganuntargetedmultiplatformapproach
AT helmynada plasmametabolomicandlipidomicprofilingofmetabolicdysfunctionassociatedfattyliverdiseaseinhumansusinganuntargetedmultiplatformapproach
AT vonscorinne plasmametabolomicandlipidomicprofilingofmetabolicdysfunctionassociatedfattyliverdiseaseinhumansusinganuntargetedmultiplatformapproach
AT xuguowang plasmametabolomicandlipidomicprofilingofmetabolicdysfunctionassociatedfattyliverdiseaseinhumansusinganuntargetedmultiplatformapproach
AT pripbuuscarina plasmametabolomicandlipidomicprofilingofmetabolicdysfunctionassociatedfattyliverdiseaseinhumansusinganuntargetedmultiplatformapproach
AT savarinphilippe plasmametabolomicandlipidomicprofilingofmetabolicdysfunctionassociatedfattyliverdiseaseinhumansusinganuntargetedmultiplatformapproach